How significant is the early uptake of EYLEA HD for Regeneron's growth outlook?

The $123 million in first-full-quarter U.S. sales is an early indicator of launch momentum, and management describes uptake as broad across the treatment landscape. Investors will look to subsequent quarters to confirm whether EYLEA HD can meaningfully shift patients from the original EYLEA and sustain its positioning as a next-generation anti-VEGF treatment, particularly as coverage and the permanent J-Code take effect.

Why does the $30 million Intellia charge matter if it is relatively small?

The charge is modest in dollar terms and reduces EPS by roughly $0.21 in Q4 2023. It is notable mainly because it affects both GAAP and non-GAAP results, and because it reflects a payment to extend the Intellia collaboration, which supports Regeneron's gene-editing ambitions. Regeneron does not forecast such charges, so similar items may appear unpredictably in future periods.

Are the Q4 2023 sales figures final?

No. The figures are preliminary and unaudited, and the company states that its Q4 2023 results have not been finalized and remain subject to financial statement closing procedures. Actual reported results could differ from these estimates, so investors should await the full earnings release and Form 10-K for audited figures.

What near-term catalysts should investors watch from this presentation?

Key 2024 milestones include the FDA decision on odronextamab (PDUFA March 31, 2024), the EYLEA HD permanent J-Code on April 1, 2024, the potential FDA decision on Dupixent for COPD with a Type 2 inflammatory phenotype, and BLA acceptance for linvoseltamab. Readouts from fianlimab plus cemiplimab in melanoma and the Libtayo adjuvant CSCC interim analysis are also flagged for 2024.

What are the main risks highlighted in the filing?

The forward-looking statements flag risks including the market acceptance and commercial success of EYLEA HD and EYLEA, competitive developments, reimbursement decisions by payors, supply chain and manufacturing performance, and ongoing patent litigation related to EYLEA. The presentation also references a pending civil lawsuit brought by the U.S. Attorney's Office for the District of Massachusetts, and the possibility that partner agreements, including Sanofi and Bayer, could be cancelled or terminated.

REGN 8-K: Earnings & Results & Regulation FD

01—Abstract

Summary

Summary of the 8-K filed January 8, 2024. Cited figures are marked; the original filing is the authoritative source.

Regeneron (REGN) used its appearance at the 42nd J.P.

Morgan Healthcare Conference on January 8, 2024 to furnish preliminary, unaudited fourth-quarter 2023 U.S. net product sales: approximately $123 million^a for EYLEA HD (aflibercept 8 mg), its first full quarter after FDA approval for wet AMD, DME and DR, and approximately $1.34 billion for the established EYLEA franchise. Combined U.S. EYLEA family sales were roughly $1.46 billion. The EYLEA HD launch is the central investor focus, as management argues it can become the next-generation standard of care in anti-VEGF therapy, citing early broad uptake, roughly two-thirds of eligible lives with coverage, and a permanent J-Code expected April 1, 2024.

The filing also discloses a $30 million^b pre-tax acquired IPR&D charge in Q4 2023 tied to a payment to extend the Intellia Therapeutics collaboration. The charge is expected to reduce both GAAP and non-GAAP diluted EPS by about $0.21. Regeneron does not forecast such charges because their timing and size are uncertain, so investors should treat the reported figures as preliminary and subject to closing procedures.

The accompanying presentation (Exhibit 99.1) is a broad 2024 strategic update covering the Dupixent COPD opportunity and its pending sBLA, Libtayo growth expected to exceed $1 billion^c in 2024, linvoseltamab and odronextamab regulatory milestones, CD28 costimulatory bispecifics, obesity and genetic medicine programs, and a 2024 milestone calendar. Because the Q4 figures are unaudited and the filing is largely a forward-looking presentation, the near-term catalysts are the EYLEA HD uptake trajectory, the odronextamab and linvoseltamab regulatory decisions, and the Dupixent COPD approval timing.

02—Key points

Key Highlights

Preliminary Q4 2023 U.S. net product sales: EYLEA HD approximately $123 million, the first full quarter after its August 2023 FDA approval for wAMD, DME and DR.
Preliminary Q4 2023 U.S. net product sales of the original EYLEA were approximately $1.34 billion, bringing combined U.S. EYLEA family sales to about $1.46 billion.
A $30 million pre-tax acquired IPR&D charge for extending the Intellia Therapeutics collaboration is expected to reduce Q4 2023 GAAP and non-GAAP diluted EPS by approximately $0.21.
Management cites about two-thirds of eligible lives with EYLEA HD coverage, with most covered lives having first-line or single-step-edit access, and a permanent J-Code expected April 1, 2024.
Dupixent global net sales grew 34% to nearly $8.4 billion in the first nine months of 2023, with a COPD sBLA completed in December 2023 and under review.
Regulatory catalysts flagged for 2024 include the FDA decision on odronextamab in R/R FL and DLBCL (1Q 2024, PDUFA March 31, 2024) and BLA acceptance for linvoseltamab in R/R multiple myeloma.
Q4 2023 results remain unaudited and subject to closing procedures, and Regeneron does not forecast acquired IPR&D charges, so reported figures could change.

03—Questions

Frequently Asked Questions

How significant is the early uptake of EYLEA HD for Regeneron's growth outlook?
The $123 million in first-full-quarter U.S. sales is an early indicator of launch momentum, and management describes uptake as broad across the treatment landscape. Investors will look to subsequent quarters to confirm whether EYLEA HD can meaningfully shift patients from the original EYLEA and sustain its positioning as a next-generation anti-VEGF treatment, particularly as coverage and the permanent J-Code take effect.
Why does the $30 million Intellia charge matter if it is relatively small?
The charge is modest in dollar terms and reduces EPS by roughly $0.21 in Q4 2023. It is notable mainly because it affects both GAAP and non-GAAP results, and because it reflects a payment to extend the Intellia collaboration, which supports Regeneron's gene-editing ambitions. Regeneron does not forecast such charges, so similar items may appear unpredictably in future periods.
Are the Q4 2023 sales figures final?
No. The figures are preliminary and unaudited, and the company states that its Q4 2023 results have not been finalized and remain subject to financial statement closing procedures. Actual reported results could differ from these estimates, so investors should await the full earnings release and Form 10-K for audited figures.
What near-term catalysts should investors watch from this presentation?
Key 2024 milestones include the FDA decision on odronextamab (PDUFA March 31, 2024), the EYLEA HD permanent J-Code on April 1, 2024, the potential FDA decision on Dupixent for COPD with a Type 2 inflammatory phenotype, and BLA acceptance for linvoseltamab. Readouts from fianlimab plus cemiplimab in melanoma and the Libtayo adjuvant CSCC interim analysis are also flagged for 2024.
What are the main risks highlighted in the filing?
The forward-looking statements flag risks including the market acceptance and commercial success of EYLEA HD and EYLEA, competitive developments, reimbursement decisions by payors, supply chain and manufacturing performance, and ongoing patent litigation related to EYLEA. The presentation also references a pending civil lawsuit brought by the U.S. Attorney's Office for the District of Massachusetts, and the possibility that partner agreements, including Sanofi and Bayer, could be cancelled or terminated.

04—Continue

← View all 8-K filings